Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | FAAH | O00519 | 6/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | STK3 | Q13188 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785559 | 0.85 | MPL (0.39) | MPLGRM5CNR2FAAHKMO | |
| SCHEMBL16776377 | 0.83 | MPL (0.41) | MPLGRM5CNR2FAAHSTK4 | |
| SCHEMBL19699055 | 0.80 | CREBBP (0.42) | FYN | |
| SCHEMBL16775913 | 0.80 | MPL (0.42) | MPLGRM5CNR2FAAHKMO | |
| SCHEMBL16775980 | 0.78 | GRM5 (0.39) | GRM5GSK3BLRRK2 | |
| SCHEMBL16775904 | 0.78 | GRM5 (0.42) | GRM5CNR2FAAHFYNKMO | |
| SCHEMBL17618739 | 0.78 | GRM5 (0.42) | MPLGRM5CNR2FAAHSTK4 | |
| SCHEMBL16775908 | 0.77 | FAAH (0.39) | GRM5CNR2FAAHGSK3BSTK4 | |
| SCHEMBL19670357 | 0.77 | MPL (0.41) | MPLGRM5CNR2FAAH | |
| SCHEMBL16776203 | 0.76 | ABL1 (0.36) | GRM5FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MPL 3547/4885GRM5 3471/4885CNR2 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.